Trailing-twelve-month (TTM) revenue is $87.53 Million. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $11,242,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-04 |
| Q4 FY2025Period ended 2025-12-31 | $17,535,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-04 |
| Q1 FY2026Period ended 2026-03-31 | $18,671,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-07 |
| Q2 FY2026Period ended 2026-06-30 | $40,078,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-06 |
| TTM revenue | $87,526,000 |
Current P/S: $681,020,400 market capitalization ÷ $87,526,000 TTM revenue = 7.78x.
Market capitalization source: FMP quote. Quote observed 2026-10-06T20:00:00.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $40.08M.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T20:33:27.948Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20182018-12-31 · USD | FY20192019-12-31 · USD | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Copiktra license and related assets | N/A | N/A | N/A | $1M | N/A | N/A |
| Government rebates and other incentives | N/A |
$87.53M
$87.53 Million
N/A
(18.98%)
5 Year compound annual growth rate
1 Year
N/A
3 Year
N/A
5 Year
(18.98%)
10 Year
N/A
15 Year
N/A
20 Year
N/A
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $30.91M | +$20.91M | +209.14% |
| 2024 | $10.00M | +$7.40M | +285.21% |
| 2022 | $2.60M | +$543,000 | +26.45% |
| 2021 | $2.05M | ($86.46M) | (97.68%) |
| 2020 | $88.52M | +$71.06M | +407.08% |
| 2019 |
TTM Growth
N/A
3-Year CAGR
N/A
5-Year CAGR
(18.98%)
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 17 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-06T20:33:27.948Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
| N/A |
| $67,000 |
| N/A |
| $4M |
| Product Revenue And Allowances Returns | $2,000 | $76,000 | $31,000 | N/A | N/A | N/A |
|---|
| Product Revenue Reserves And Allowances Government Rebates And Other Incentives | $157,000 | $372,000 | $67,000 | N/A | N/A | N/A |
|---|
| Product Revenue Reserves And Allowances Third Party Payer Chargebacks Discounts And Fees | $88,000 | $255,000 | $2M | N/A | N/A | N/A |
|---|
| Product Revenue Reserves And Allowances Trade Discounts And Allowances | $29,000 | $111,000 | $23,000 | N/A | N/A | N/A |
|---|
| Returns | N/A | N/A | N/A | $31,000 | N/A | $376,000 |
|---|
| Sale of COPIKTRA license and related assets | N/A | N/A | N/A | N/A | $3M | N/A |
|---|
| Trade discounts and allowances | N/A | N/A | N/A | $23,000 | N/A | $888,000 |
|---|
| $17.46M |
| ($9.26M) |
| (34.67%) |
